AZD 8108

Drug Profile

AZD 8108

Alternative Names: AZD8108

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Suicidal ideation

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Suicidal-ideation(In volunteers) in USA (PO, Liquid)
  • 06 Feb 2017 AstraZeneca divests the development of AZD 8108 to an unknown company (AstraZeneca pipeline, February 2017)
  • 01 Nov 2014 Phase-I clinical trials in Suicidal ideation (In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top